Prostate cancer (PCa) is the most common malignancy, and the third leading cancer-related
cause of death among men of the Western world. Upon PCa progression into metastatic …

Multiple mechanisms of resistance contribute to the inevitable progression of hormone-
sensitive prostate cancer to castration-resistant prostate cancer (CRPC). Currently approved …

Introduction: Prostate cancer is the second most common cancer death in men after lung
cancer, due to distant metastases. While distant prostate cancer is typically castrate …

Various molecular mechanisms have been implicated in the progression from hormone‐
sensitive to castration‐resistant prostate cancer (CRPC). Novel targeted agents to treat …

Castrate resistant prostate cancer (CRPC) is the fatal-form of prostate cancer and remains
androgen dependent. The reactivation of the androgen axis occurs due to adaptive …

Resistance of castration‐resistant prostate cancer (CRPC) to enzalutamide and abiraterone
involves the expression of constitutively active, truncated androgen receptor (AR) splice …

The growth and dependence of Prostate Cancer (PCa) on androgen stimulation led to the
use of castration to reduce circulating levels of androgens and anti-androgens to directly …

Background: Recent observations implicate persistent androgen signaling in metastatic
castrate-resistant prostate cancer (mCRPC) progression. Inhibition of CYP 17 lyase with …

The treatment landscape of castration-resistant prostate cancer (CRPC) has been
dramatically changed over the past years with the approval of several new drugs for clinical …

Androgen-targeted therapy aimed at abrogating androgen receptor (AR) mediated growth is
the mainstay of treatment of advanced prostate cancer. Targeting of microtubules (taxane …